ASTRAZENECA: US Synagis rights sold to Sobi for USD1.5bn upfront | NEUTRAL | 5700p
ASTRAZENECA - NEUTRAL | 5700p(-9%)US Synagis rights sold to Sobi for USD1.5bn upfront
Busy fourth-quarter for divestment agreements
An upfront payment of USD1.5bn, of which USD1bn in cash
The transaction answers part of the question about OOI in 2019
We stick to our NEUTRAL rating
AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.